Technical Data
B0003-05N2
Bacillus anthracis PA, Protective Antigen (Anthrax)
Description:
Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF) (1,2 for review). PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) (3) and capillary morphogenesis protein 2 (CMG2) (4), although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF; the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm (5). These toxins are usually sufficient to cause rapid cell death, and often the death of the organism.

Applications:
Suitable for use in ELISA. Other applications have not been tested.

Recommended Dilution:
ELISA: 1ug/ml will detect 10ng free peptide of PA protein.
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile glycerol (40-50%), aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ug4C (-20C Glycerol)Blue IceRabbit
Concentration:
~1mg/ml
Immunogen:
Synthetic peptide corresponding to 14aa at the carboxy-terminus of the Anthrax protective antigen protein (Genbank accession no. AAF86457).
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 0.02% sodium azide.
Specificity:
Recognizes Anthrax PA (CT).
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Schwartz, M.N., New Engl. J. Med. 345: 1621-1626 (2001). 2. Moayeri, M. & Leppla, S.H., Curr. Opin. Microbiol. 7: 19-24 (2004). 3. Bradley, K.A., et al., Nature 414: 225-229 (2001). 4. Scobie, H.M., et al., Proc. Natl. Acad. Sci. USA 100: 5170-5174 (2003). 5. Singh, Y., et al., Infect. Immun. 67: 1853-1859 (1999).